Developer docs
API playgroundTry for free, no card

Search company profiles

Bio Elpida

Full company profile

uuid003opv2

Namestring
Bio Elpida
Websiteurl
bio-elpida.com
Company typeenum
Private
Founded yearint
2009
Short descriptiontext

Bio Elpida is a privately held French biotechnology contract development and manufacturing organization (CDMO) based in Lyon, founded in 2009, serving biotech and pharmaceutical clients with a small 11-50 person team.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
biopharmaceutical manufacturing, contract development services, biologics manufacturing, biotech CDMO services, process development biologics
Industry3 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
Biopharmaceutical CDMO Services
Social media profiles1 record
Cost components4 values
Personnel, Operations, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Bio Elpida is a biotechnology contract development and manufacturing organization (CDMO) based in Lyon, France. It provides development and manufacturing services to biotechnology clients. Founded in 2009, the company's public website is currently under construction and redirects visitors to the Sartorius corporate site.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Biotechnology contract development and manufacturing services
CategoryContract Development and Manufacturing Organization (CDMO)
No data
Peers10 records
TypeBroad incumbent
Description

Catalent is a major global CDMO covering biologics, cell therapy, and fill-finish services. It is comparable to Bio Elpida on the contract development and manufacturing business model, though at vastly larger scale and broader modality coverage.

TypeBroad incumbent
Description

Sartorius is a leading bioprocessing and CDMO solutions provider whose site is the redirect target from bio-elpida.com. The explicit digital handoff strongly suggests an ownership or partnership relationship, making Sartorius the most directly relevant reference peer.

TypeBroad incumbent
Description

Samsung Biologics is a top-tier biologics CDMO with large-scale mammalian drug substance and aseptic fill-finish capacity. It competes for the same biotech outsourcing programmes and serves as a scale benchmark for a small CDMO like Bio Elpida.

TypeBroad incumbent
Description

Lonza is the world's largest biologics CDMO offering mammalian and microbial development, drug substance and drug product manufacturing. Compared to Bio Elpida, Lonza is the full-scale incumbent benchmark for biotech contract manufacturing services globally.

TypeBroad incumbent
Description

WuXi Biologics offers end-to-end biologics development, manufacturing, and testing services globally. It is comparable to Bio Elpida as a contract development and manufacturing services provider in the biotechnology space, though operating at a much larger scale.

TypeDirect peer
Description

AGC Biologics is a mid-sized CDMO providing mammalian and microbial biologics development and manufacturing services. It is the closest mid-market scale peer to a 11-50 employee European CDMO like Bio Elpida, both targeting biotech customers with outsourced process development and GMP production.

TypeDirect peer
Description

Rentschler Biopharma is a European (German) CDMO focused on mammalian cell culture-based biologics manufacturing for biotech clients. It is directly comparable to Bio Elpida on geography (Central Europe), business model (CDMO), and biotech target customer base.

TypeRegional player
Description

Novasep is a French-headquartered CDMO with biologics, viral vectors, and small-molecule manufacturing capabilities. Its French base and contract development and manufacturing services portfolio make it a closely comparable regional peer to Bio Elpida in Lyon.

9Boehringer Ingelheim BioXcellence
TypeBroad incumbent
Description

Boehringer Ingelheim's BioXcellence business is a dedicated biologics CDMO offering contract manufacturing of mAbs and recombinant proteins, highly analogous to Bio Elpida's stated biotech CDMO scope.

TypeBroad incumbent
Description

Eurofins operates a global CDMO and biopharma product testing network with a French presence, offering contract development, manufacturing, and quality/testing services. It is comparable to Bio Elpida on biotech contract services scope and European footprint.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bio Elpida

Biopharmaceutical CDMO Servicesbio-elpida.com

Bio Elpida is a privately held French biotechnology contract development and manufacturing organization (CDMO) based in Lyon, founded in 2009, serving biotech and pharmaceutical clients with a small 11-50 person team.

Bio Elpida firmographics

Firmographics
Name
Bio Elpida
Website
https://bio-elpida.com
Company type
Private
Founded year
2009
Headcount range
11–50 employees
Short description
Bio Elpida is a privately held French biotechnology contract development and manufacturing organization (CDMO) based in Lyon, founded in 2009, serving biotech and pharmaceutical clients with a small 11-50 person team.
Ownership category
akta.pro rank

Bio Elpida industry classification

Industry
Product category
Biopharmaceutical CDMO Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Biopharmaceutical manufacturing
  • Contract development services
  • Biologics manufacturing
  • Biotech CDMO services
  • Process development biologics

Where Bio Elpida is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Markets served

Bio Elpida business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure

Bio Elpida product offering

Product offering

Core offering

Bio Elpida is a biotechnology contract development and manufacturing organization (CDMO) based in Lyon, France. It provides development and manufacturing services to biotechnology clients. Founded in 2009, the company's public website is currently under construction and redirects visitors to the Sartorius corporate site.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biotechnology contract development and manufacturing services

Companies that use Bio Elpida

Customer profile

Ideal customer profiles1 record

Bio Elpida technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Bio Elpida competitors and assessment

Company assessment

Broad incumbents

  • Catalent: Catalent is a major global CDMO covering biologics, cell therapy, and fill-finish services. It is comparable to Bio Elpida on the contract development and manufacturing business model, though at vastly larger scale and broader modality coverage.
  • Sartorius AG: Sartorius is a leading bioprocessing and CDMO solutions provider whose site is the redirect target from bio-elpida.com. The explicit digital handoff strongly suggests an ownership or partnership relationship, making Sartorius the most directly relevant reference peer.
  • Samsung Biologics: Samsung Biologics is a top-tier biologics CDMO with large-scale mammalian drug substance and aseptic fill-finish capacity. It competes for the same biotech outsourcing programmes and serves as a scale benchmark for a small CDMO like Bio Elpida.
  • Lonza Group: Lonza is the world's largest biologics CDMO offering mammalian and microbial development, drug substance and drug product manufacturing. Compared to Bio Elpida, Lonza is the full-scale incumbent benchmark for biotech contract manufacturing services globally.
  • WuXi Biologics: WuXi Biologics offers end-to-end biologics development, manufacturing, and testing services globally. It is comparable to Bio Elpida as a contract development and manufacturing services provider in the biotechnology space, though operating at a much larger scale.
  • Boehringer Ingelheim BioXcellence: Boehringer Ingelheim's BioXcellence business is a dedicated biologics CDMO offering contract manufacturing of mAbs and recombinant proteins, highly analogous to Bio Elpida's stated biotech CDMO scope.
  • Eurofins CDMO: Eurofins operates a global CDMO and biopharma product testing network with a French presence, offering contract development, manufacturing, and quality/testing services. It is comparable to Bio Elpida on biotech contract services scope and European footprint.

Direct peers

  • AGC Biologics: AGC Biologics is a mid-sized CDMO providing mammalian and microbial biologics development and manufacturing services. It is the closest mid-market scale peer to a 11-50 employee European CDMO like Bio Elpida, both targeting biotech customers with outsourced process development and GMP production.
  • Rentschler Biopharma: Rentschler Biopharma is a European (German) CDMO focused on mammalian cell culture-based biologics manufacturing for biotech clients. It is directly comparable to Bio Elpida on geography (Central Europe), business model (CDMO), and biotech target customer base.

Regional players

  • Novasep: Novasep is a French-headquartered CDMO with biologics, viral vectors, and small-molecule manufacturing capabilities. Its French base and contract development and manufacturing services portfolio make it a closely comparable regional peer to Bio Elpida in Lyon.

Market position

Customer concentration

Bio Elpida social profiles

Digital presence

Bio Elpida financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bio Elpida leadership team

Management profile

Number of profiles

Profiles1 record

Bio Elpida funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bio Elpida M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bio Elpida

What does Bio Elpida do?

Bio Elpida is a biotechnology contract development and manufacturing organization (CDMO) based in Lyon, France. It provides development and manufacturing services to biotechnology clients. Founded in 2009, the company's public website is currently under construction and redirects visitors to the Sartorius corporate site.

When was Bio Elpida founded?

Bio Elpida was founded in 2009. It employs 11 to 50 people.

Where is Bio Elpida based?

Bio Elpida is headquartered in Lyon, France, in the Europe region.

Who are Bio Elpida's main competitors?

Broad incumbents on record are Catalent, Sartorius AG, Samsung Biologics, Lonza Group, WuXi Biologics, Boehringer Ingelheim BioXcellence and Eurofins CDMO. Direct peers are AGC Biologics and Rentschler Biopharma. Novasep is listed as a regional player.

Does Bio Elpida have an API?

No public API is recorded for Bio Elpida.

What industry is Bio Elpida in?

Bio Elpida's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireBioElpida, partenaire de fabrication biologique, termine la prochaine phase de production de BPF BVX-0918 pour une étude clinique de l'UEBioVaxys Technology Corp. announced that its bioproduction partner BioElpida has completed the creation of OVCAR-3 cell banks, a critical step for Good Manufacturing Practice (GMP) production of its ovarian cancer vaccine candidate BVX-0918. This milestone advances the development process and positions the company for an upcoming Phase I clinical study in the European Union scheduled for later in 2022.PR NewswireBioproduktionspartner BioElpida schließt nächste Phase der GMP-Produktion von BVX-0918 für klinische EU-Studie abBioVaxys announced that its partner BioElpida completed the creation of OVCAR-3 cell banks, a key step in the GMP manufacturing process for its ovarian cancer vaccine candidate BVX-0918. The company also established collaborations with Hospices Civils de Lyon and the Deaconess Research Institute to validate tumor procurement and logistics for upcoming Phase I clinical trials in the EU. These developments mark progress toward producing BVX-0918 in GMP quality for potential patient use in the United States and Europe.PR NewswireEl socio bio-fabricante BioElpida completa la siguiente fase de la producción GMP de BVX-0918BioElpida has completed the creation of multiple OVCAR-3 cell banks, a critical step in establishing Good Manufacturing Practice (GMP) production for BioVaxys' ovarian cancer vaccine candidate, BVX-0918. This milestone supports regulatory requirements from the EU and US and advances the company toward its planned Phase I clinical study in Europe scheduled for late 2022. The development involves collaboration with Hospices Civils de Lyon and the Deaconess Research Institute to validate tumor collection and supply chain logistics.PR NewswireBio Elpida, partenaire de BioVaxys pour la fabrication d'un vaccin contre le cancer, franchit une étape importante de la bioproductionBio Elpida has completed the technological process transfer for BioVaxys' ovarian cancer vaccine candidate BVX-0918A and initiated development using a quality-by-design approach. The partnership is preparing for Good Manufacturing Practice (GMP) production while planning to validate the manufacturing process using patient tumor samples. This milestone precedes the planned Phase I clinical trial in Spain scheduled for early next year.PR NewswireBioVaxys und Bioproduktionspartner Bio Elpida beginnen mit dem Bau einer GMP-Anlage zur Produktion von klinischem Material für die geplante Impfstoffstudie gegen EierstockkrebsBioVaxys Technology Corp.'s bioproduction partner Bio Elpida has begun constructing a new GMP cleanroom facility in Lyon, France, for manufacturing BVX-0918A, the company's ovarian cancer vaccine candidate. The facility, planned for completion by end of 2021, is designed to enable receipt of ovarian tumor biopsies and treatment within a short timeframe. The two-phase development process includes a feasibility study followed by GMP production and testing of clinical samples for a planned EU Phase I/II clinical trial in Q2 next year.PR NewswireBioVaxys y Bio Elpida inician la construcción de una instalación GMPBioVaxys Technology Corp. and its bioproduction partner Bio Elpida in Lyon, France, have begun construction of a GMP cleanroom facility to produce clinical supply for BVX-0918A, BioVaxys' ovarian cancer vaccine candidate. The facility is expected to be completed by the end of 2021, and the two-phase bioproduction development process includes a feasibility study currently underway, followed by manufacturing and testing of clinical samples for a Phase I/II clinical trial in the EU planned for Q2 2022. The construction aligns with Bio Elpida's strategy to remain a leader in specific cancer vaccine production services.PR NewswireBiotechs Zero in on Growing Ovarian Cancer Market as Pivotal Trials Advance Through Regulatory AgenciesBioVaxys Technology Corp. has signed a definitive exclusive agreement with BioElpida S.A.S. to begin clinical-grade bioproduction and aseptic packaging for its ovarian cancer vaccine candidate, BXV-0918A. The company plans to submit a regulatory application for an EU Phase I study by the end of 2021, with vaccine supply available in early May 2022.PR NewswireBioVaxys et BioElpida signent une liste de conditions pour la bioproduction de qualité clinique du BVX-0918ABioVaxys Technology Corp. and BioElpida S.A.S. have signed a list of conditions to collaborate on the clinical-grade bioproduction and aseptic packaging of BioVaxys' ovarian cancer vaccine, BVX-0918A. The companies aim to finalize a definitive agreement by the end of March 2021, with process development expected to conclude within the year ahead of a planned Phase I/II clinical trial in the European Union.